Edgewise Therapeutics, Inc. Share Price & Technical Analysis
EWTX · $36.68 (-1.53%)
Healthcare / Biotechnology
$36.68
-1.53%
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company …
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-8% return in Jun, -9% avg return in past 3 year Jun month.
24% return in 2026, 60% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 12% | 8% | 5% | -3% | 10% | -8% | – | – | – | – | – | – | 24% |
| 25 | 4% | -6% | -15% | -25% | -13% | -9% | 9% | 2% | 12% | 14% | 42% | -5% | 10% |
| 24 | 63% | -9% | 12% | -2% | -5% | 3% | -6% | 10% | 42% | 24% | -2% | -19% | 111% |
| 23 | 13% | -6% | -31% | 31% | 11% | -23% | -4% | -14% | -10% | 12% | -5% | 82% | 58% |
| 22 | -7% | -14% | -18% | -18% | -22% | 29% | 21% | 6% | -3% | -4% | -7% | -1% | -37% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.06B
P/E ratio
—
52W high
$40.77
52W low
$12.15
Volume
7,27,127
Beta
0.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Edgewise Therapeutics, Inc. share price today?
- Edgewise Therapeutics, Inc. (EWTX) last traded around $36.68 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does EWTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for EWTX. Download the app for real-time alerts.
- How can I analyze Edgewise Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.